$METIS TECHBIO-P(07666.HK)$METIS TECHBIO-P(07666.HK)thank you for great return
Overview
METIS TECHBIO-P (7666)
Metis TechBio Co., Ltd. engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based l...
- Open
- 8.110
- High
- 8.650
- Low
- 7.600
- Prev. Close
- 8.360
- Volume
- 9.19M
- Turnover
- 75.08M
- Avg Price
- 8.172
- Bid/Ask Ratio
- 7.94%
- Amplitude
- 12.56%
- 52wk High
- 29.980
- Volume Ratio
- 6.61
- Turnover Ratio
- 0.85%
- 52wk Low
- 7.600
- HK Mkt Cap
- 9.17B
- Market CapHKD
- 10.01B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.344
- EPSDynamic
- -0.298
- EPSStatic
- --
- BVPS
- 2.94
- P/B
- 2.88
- HK Shares
- 1.08B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.18B
- Min lot size
- 500
- Currency
- HKD
METIS TECHBIO-P Analyst Rating
View moreForecast & Rating
Nov 3, 2026- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 3
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
METiS TechBio (7666.HK) reversed an early slide on Monday, closing at HK$8.465, up 1.26% from HK$8.360, after dipping to HK$7.665, a fresh 52-week low, then rebounding to HK$8.595 intraday on HK$74.8 million turnover. The recent weakness traces to the cornerstone investor lock-up expiry, which drove a 12% single-day drop on Friday and a 24.89% weekly decline; today's move reads as a repair bounce after that supply cleared. Fundamentals contrast with the price action: Q2 2026 revenue reached HK$89.1 million, up more than 140-fold year on year, while the net loss narrowed 15.67% to HK$88.5 million, leaving net margin at -99.3% and per-share loss at HK$0.0972, with price-to-book at 2.88. The US$1.1 billion AI drug-delivery agreement with Eli Lilly remains the central narrative. At HK$8.465 the stock sits 71.76% below its 52-week high of HK$29.98, down 64.43% year to date, and well under its MA20 of HK$10.763 and MA60 of HK$13.61, though the post-lock-up overhang may still need absorbing.
- Nov, 13
METiS TechBio (7666.HK) reversed early gains and weakened through the afternoon, closing at HK$8.36 versus HK$10.41 previously, a 19.69% drop, driven by concerns around the cornerstone investor lock-up expiring tomorrow and a continued fading of the excitement that followed October's US$1.1 billion AI drug-delivery pact with Eli Lilly. The stock opened at HK$10.00, briefly rebounded to HK$9.445 in the morning session, then slid to HK$8.08 in the afternoon, essentially matching yesterday's 52-week low of HK$8.075, on 31.63 million shares worth HK$283 million. Fundamentals run the other way: Q2 2026 revenue reached HK$89.1 million, up more than 140-fold year on year, while the net loss of HK$88.48 million narrowed 15.67% and the net margin stayed at -99.3%. The shares are down 64.87% year to date, 72.11% below the 52-week high of HK$29.98, and sit well beneath the MA20 of HK$10.94 and MA60 of HK$13.72. However, the absolute loss is still close to HK$88 million, with no clear timing yet on a turnaround.
- Nov, 12
METiS TechBio (7666.HK) fell 6.55% to HK$10.41 on Thursday in a spike-and-fade session, dragged by the cornerstone investor lock-up expiring tomorrow: it opened at HK$11.40 and slid to an intraday low of HK$10.38 at 15:57 BJ on HK$424m turnover. The earlier US$1.1bn AI drug-delivery pact with Eli Lilly had lifted the shares 6% in one session, but that momentum has unwound; the stock is down 56.26% year-to-date, 65.28% below its 52-week high of HK$29.98 set on 12 May, only about 10% above the HK$9.46 low, and below both the MA20 of HK$11.08 and MA60 of HK$13.77. Fundamentals remain loss-making: Q2 revenue of HK$89.1m against a net loss of HK$88.5m, narrowed 15.67% yoy, with net margin at -99.30%, PB 3.54x and PE -30.25x. Still, rising revenue and a narrowing loss indicate the AI nano-materials platform is progressing commercially.
- Nov, 6
Shares gapped down 2.6% to HK$10.50, probed lower, then rebounded to an intraday high of HK$11.12 at 10:21 BJ before consolidating between HK$10.85 and HK$11.05 in the afternoon session and closing at HK$10.99, down 2.57% on 2.356 million shares worth HK$25.7 million, a 0.24% turnover rate. The overhang is the approaching expiry of cornerstone investors' lock-up, with the stock named in November's Hong Kong unlocking list after already falling 6% the prior session; inclusion in the HKEX Artificial Intelligence Index, the US$1.1 billion AI-LNP order from Eli Lilly and AiLNP platform endorsement by an international pharmaceutical company failed to extend momentum. Q2 revenue reached HK$89.1 million against a net loss of HK$88.5 million, narrowing 15.67% yoy, while net margin stayed at -99.3% and PB at 3.74x, contrasting with a price still -53.82% YTD, 63.34% below the 52-week high of HK$29.98 and under both MA20 (11.416) and MA60 (13.871). It nonetheless sits 16.17% above the July 29 low of HK$9.46, though event-driven swings may persist until the unlocked shares are absorbed.
- Nov, 4
An 8.1% gain to HK$11.10 lifted 7666.HK from a flat open to an intraday high of HK$11.42 at 14:33 BJ, powered by its addition to the HKEX Artificial Intelligence Index and follow-through from the US$1.1 billion AI-LNP order with Eli Lilly; morning trade idled between HK$10.32 and HK$10.78 before afternoon buying pushed the stock up, and it settled at HK$11.13 on 6.554 million shares worth HK$71.1 million. Q2 2026 revenue of HK$89.1 million, up more than 140-fold year on year, sits alongside a narrower net loss of HK$88.5 million (-15.67% yoy) and a still-negative 99.3% net margin, giving a PE of -32.25 and PB of 3.78. The rebound still leaves the shares down 53.36% year to date, 62.98% below the HK$29.98 52-week high and under both MA20 of HK$11.93 and MA60 of HK$13.91, though 17.34% above the HK$9.46 low. Still, the close gave back nearly HK$0.3 from the high, pointing to limited follow-through.
News
Market Movers · Metis TechBio drops 5%
Weekly Review · Weekly Recap | METIS TECHBIO-P -24.89%, lock-up expiry drives the week
Market Movers · Metis Techbio tumbles 12%
Market Movers · Metis Techbio falls 6% as cornerstone investor lock-up ends tomorrow
Weekly Review · Weekly Recap | METIS TECHBIO-P +1.38%, consensus target above spot
Market Movers · Metis TechBio falls 6% as cornerstone lock-up expiry nears
Posts
View more- KTrade Showcase: Trade, Show & Earn Rewards!
- ZZhang Johnaten
Total Assets
Traded Value$METIS TECHBIO-P(07666.HK) What a lousy stock, keeps falling. Your management is useless and inactive, are you screwing over shareholders?

